Literature DB >> 16257844

Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? A 1-year follow-up study.

Terhi Martikainen1, Agneta Ekstrand, Eero Honkanen, Anna-Maija Teppo, Carola Grönhagen-Riska.   

Abstract

OBJECTIVE: Diminishing ultrafiltration and dialysis adequacy may limit the long-term use of peritoneal dialysis (PD). Inflammation may play a role in changes in peritoneal function. This study was designed to evaluate alterations in peritoneal function and soluble factors in dialysate during a 1-year follow-up period.
MATERIAL AND METHODS: A personal dialysis capacity test was performed at the start of the study and after 6 and 12 months in 20 patients in order to determine dialysis adequacy and membrane characteristics. Dialysate was collected during the test days for analyses of interleukin-6 (IL-6), soluble intercellular adhesion molecule-1, hyaluronan and cancer antigen 125 (CA125).
RESULTS: There were no significant changes in dialysis adequacy or membrane characteristics during the 1-year follow-up period. The appearance rate of IL-6 in dialysate increased significantly (419.8+/-63.3 at the start, 784.1+/-136.4 after 6 months and 1149.3+/-252.2 ng/24 h after 12 months; p=0.006) during follow-up. Furthermore, the appearance rate of CA125 increased throughout the study in patients using icodextrin, but decreased slightly in patients using only conventional dialysis solutions.
CONCLUSIONS: There were no major changes in dialysis adequacy or membrane characteristics during the follow-up period, but increased IL-6 in dialysate may reflect peritoneal inflammation, which may lead to long-term alterations in the peritoneal membrane. Icodextrin may have a preventive effect on the longevity of the peritoneal membrane.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257844     DOI: 10.1080/00365590500386809

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  8 in total

1.  Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial.

Authors:  Yuji Takatori; Shigeru Akagi; Hitoshi Sugiyama; Junko Inoue; Shoichiro Kojo; Hiroshi Morinaga; Kazushi Nakao; Jun Wada; Hirofumi Makino
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

2.  Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival.

Authors:  Mark Lambie; James Chess; Kieron L Donovan; Yong Lim Kim; Jun Young Do; Hi Bahl Lee; Hyunjin Noh; Paul F Williams; Andrew J Williams; Sara Davison; Marc Dorval; Angela Summers; John D Williams; John Bankart; Simon J Davies; Nicholas Topley
Journal:  J Am Soc Nephrol       Date:  2013-09-05       Impact factor: 10.121

3.  Icodextrin produces higher ultrafiltration in diabetic than in non-diabetic patients on continuous cyclic peritoneal dialysis.

Authors:  Mufazzal Ahmad; Tarun Jeloka; Theodoros Pliakogiannis; Shruti Tapiawala; Hui Zhong; Joanne M Bargman; Dimitrios Oreopoulos
Journal:  Int Urol Nephrol       Date:  2007-11-08       Impact factor: 2.370

Review 4.  Peritoneal changes in patients on long-term peritoneal dialysis.

Authors:  Raymond T Krediet; Dirk G Struijk
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

Review 5.  Dialysate cancer antigen 125 in long-term peritoneal dialysis patients.

Authors:  Panida Ditsawanon; Ouppatham Supasyndh; Pornanong Aramwit
Journal:  Clin Exp Nephrol       Date:  2013-06-12       Impact factor: 2.801

Review 6.  Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.

Authors:  Mufazzal Ahmad; Hemal Shah; Theodori Pliakogiannis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006-09-27       Impact factor: 2.266

7.  Monitoring of the peritoneal membrane.

Authors:  Dirk G Struijk
Journal:  NDT Plus       Date:  2008-10

8.  Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.

Authors:  Hye Eun Yoon; Yoon Kyung Chang; Seok Joon Shin; Bum Soon Choi; Byung Soo Kim; Cheol Whee Park; Ho Cheol Song; Sun Ae Yoon; Dong Chan Jin; Yong-Soo Kim
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.